Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW003 in Obese Participants With Obstructive Sleep Apnea
NCT07387094Phase 3Recruiting
- Sponsor
- Sciwind Biosciences
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of ecnoglutide in obstructive sleep apnea (OSA), obesity, sponsored by Sciwind Biosciences. Started Feb 2026; status: recruiting.
02
Drugs
ecnoglutide
03
Conditions
obstructive sleep apnea (OSA)obesity
Beyond the preview
Go deeper on NCT07387094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387094.